| Nonmotor fluctuations in Parkinson’s disease: frequent and disabling T Witjas, E Kaphan, JP Azulay, O Blin, M Ceccaldi, J Pouget, M Poncet, ... Neurology 59 (3), 408-413, 2002 | 881 | 2002 |
| Staphylococcus aureus Nasal Colonization: An Update on Mechanisms, Epidemiology, Risk Factors, and Subsequent Infections A Sakr, F Brégeon, JL Mège, JM Rolain, O Blin Frontiers in microbiology 9, 2419, 2018 | 559 | 2018 |
| Quantitative analysis of gait in Parkinson patients: increased variability of stride length O Blin, AM Ferrandez, G Serratrice Journal of the neurological sciences 98 (1), 91-97, 1990 | 488 | 1990 |
| Visual control of locomotion in Parkinson's disease JP Azulay, S Mesure, B Amblard, O Blin, I Sangla, J Pouget Brain 122 (1), 111-120, 1999 | 461 | 1999 |
| Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial CM Beasley, SH Hamilton, AM Crawford, MA Dellva, GD Tollefson, ... European Neuropsychopharmacology 7 (2), 125-137, 1997 | 426 | 1997 |
| Dopa-sensitive and dopa-resistant gait parameters in Parkinson's disease O Blin, AM Ferrandez, J Pailhous, G Serratrice Journal of the neurological sciences 103 (1), 51-54, 1991 | 338 | 1991 |
| Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti‐GM1 antibodies: A double‐blind, placebo‐controlled study JP Azulay, O Blin, J Pouget, J Boucraut, F Bille-Turc, G Carles, ... Neurology 44 (3_part_1), 429-429, 1994 | 321 | 1994 |
| Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study RA Emsley, Risperidone Working Group Schizophrenia bulletin 25 (4), 721-729, 1999 | 272 | 1999 |
| Peyro Saint Paul H, Azulay JP, et al: Mitochondrial respiratory failure in skeletal muscle from patients with Parkinson’s disease and multiple system atrophy O Blin, C Desnuelle, O Rascol, M Borg J Neurol Sci 125, 95-101, 1994 | 209* | 1994 |
| Influence of visual cues on gait in Parkinson's disease: contribution to attention or sensory dependence? JP Azulay, S Mesure, O Blin Journal of the neurological sciences 248 (1-2), 192-195, 2006 | 206 | 2006 |
| Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: a double‐blind controlled study in general practice N Nguyen, E Fakra, V Pradel, E Jouve, C Alquier, ME Le Guern, J Micallef, ... Human Psychopharmacology: Clinical and Experimental 21 (3), 139-149, 2006 | 190 | 2006 |
| Dopaminergic contribution to the regulation of emotional perception P Salgado-Pineda, P Delaveau, O Blin, A Nieoullon Clinical neuropharmacology 28 (5), 228, 2005 | 189 | 2005 |
| Disease tracking markers for Alzheimer's disease at the prodromal (MCI) stage V Drago, C Babiloni, D Bartrés-Faz, A Caroli, B Bosch, T Hensch, M Didic, ... Journal of Alzheimer's disease 26 (s3), 159-199, 2011 | 188 | 2011 |
| A comparative review of new antipsychotics O Blin Canadian journal of psychiatry 44, 235-244, 1999 | 182 | 1999 |
| Brain morphometry reproducibility in multi-center 3 T MRI studies: a comparison of cross-sectional and longitudinal segmentations J Jovicich, M Marizzoni, R Sala-Llonch, B Bosch, D Bartrés-Faz, J Arnold, ... Neuroimage 83, 472-484, 2013 | 179 | 2013 |
| The grey mouse lemur: a non-human primate model for ageing studies S Languille, S Blanc, O Blin, CI Canale, A Dal-Pan, G Devau, M Dhenain, ... Ageing research reviews 11 (1), 150-162, 2012 | 176 | 2012 |
| Neural bases of different cognitive strategies for facial affect processing in schizophrenia E Fakra, P Salgado-Pineda, P Delaveau, AR Hariri, O Blin Schizophrenia research 100 (1-3), 191-205, 2008 | 176 | 2008 |
| Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease O Rascol, JG Nutt, O Blin, CG Goetz, JM Trugman, C Soubrouillard, ... Archives of neurology 58 (2), 249-254, 2001 | 174 | 2001 |
| Effect of ascorbic acid in patients with Charcot–Marie–Tooth disease type 1A: a multicentre, randomised, double-blind, placebo-controlled trial J Micallef, S Attarian, O Dubourg, PM Gonnaud, JY Hogrel, T Stojkovic, ... The Lancet Neurology 8 (12), 1103-1110, 2009 | 160 | 2009 |
| Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients O Blin, JM Azorin, P Bouhours Journal of Clinical Psychopharmacology 16 (1), 38-44, 1996 | 159 | 1996 |
